BioMarin Pharmaceutical (BMRN) – Analysts’ Weekly Ratings Changes

Several brokerages have updated their recommendations and price targets on shares of BioMarin Pharmaceutical (NASDAQ: BMRN) in the last few weeks:

• 11/3/2026 – BioMarin Pharmaceutical had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 11/3/2026 – BioMarin Pharmaceutical had its price target lowered by Oppenheimer from $97.00 to $94.00. They now have an “outperform” rating on the stock.
• 11/3/2026 – BioMarin Pharmaceutical had its price target lowered by Stifel Nicolaus from $70.00 to $66.00. They now have a “hold” rating on the stock.
• 11/3/2026 – BioMarin Pharmaceutical had its price target lowered by Morgan Stanley from $122.00 to $119.00. They now have an “overweight” rating on the stock.
• 11/3/2026 – BioMarin Pharmaceutical had its “neutral” rating reaffirmed by HC Wainwright. They now have a $60.00 price target on the stock.
• 11/3/2026 – BioMarin Pharmaceutical had its price target lowered by Royal Bank Of Canada from $62.00 to $60.00. They now have a “sector perform” rating on the stock.
• 10/31/2026 – BioMarin Pharmaceutical was downgraded by Wall Street Zen from “buy” to “hold”.
• 10/21/2026 – BioMarin Pharmaceutical had its price target lowered by Morgan Stanley from $124.00 to $122.00. They now have an “overweight” rating on the stock.
• 10/20/2026 – BioMarin Pharmaceutical had its price target raised by JPMorgan Chase & Co. from $86.00 to $87.00. They now have an “overweight” rating on the stock.
• 10/20/2026 – BioMarin Pharmaceutical had its “overweight” rating reaffirmed by Cantor Fitzgerald. They now have a $86.00 price target on the stock.
• 10/15/2026 – BioMarin Pharmaceutical is now covered by UBS Group. They set a “buy” rating and a $88.00 price target on the stock.
• 10/14/2026 – BioMarin Pharmaceutical was upgraded by UBS Group to “strong-buy”.
• 10/14/2026 – BioMarin Pharmaceutical had its price target raised by Barclays from $111.00 to $114.00. They now have an “overweight” rating on the stock.
• 10/12/2026 – BioMarin Pharmaceutical was upgraded by Raymond James Financial from “outperform” to “strong-buy”. They now have a $109.00 price target on the stock.
• 9/23/2026 – BioMarin Pharmaceutical was upgraded by William Blair to “hold”.
• 9/18/2026 – BioMarin Pharmaceutical was downgraded by Weiss Ratings from “sell (d+)” to “sell (d)”.
• 9/16/2026 – BioMarin Pharmaceutical had its “outperform” rating reaffirmed by BMO Capital Markets.
• 9/10/2026 – BioMarin Pharmaceutical had its “neutral” rating reaffirmed by HC Wainwright. They now have a $60.00 price target on the stock.

BioMarin Pharmaceutical Trading Up 1.5%

BMRN traded up $0.83 during trading on Wednesday, reaching $56.49. The company had a trading volume of 316,370 shares, compared to its average volume of 2,116,428. The stock has a market cap of $10.93 billion, a P/E ratio of -564.86, a PEG ratio of 0.63 and a beta of 0.21. The business has a 50 day simple moving average of $60.24 and a 200-day simple moving average of $58.45. BioMarin Pharmaceutical Inc. has a 52 week low of $49.26 and a 52 week high of $70.98. The company has a quick ratio of 1.32, a current ratio of 2.39 and a debt-to-equity ratio of 0.56.

BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its quarterly earnings data on Monday, November 2nd. The biotechnology company reported $0.23 EPS for the quarter, beating the consensus estimate of ($0.05) by $0.28. The company had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.02 billion. BioMarin Pharmaceutical had a positive return on equity of 5.59% and a negative net margin of 0.52%. BioMarin Pharmaceutical’s quarterly revenue was up 32.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.12 EPS. On average, equities analysts anticipate that BioMarin Pharmaceutical Inc. will post 2.59 EPS for the current fiscal year.

BioMarin Pharmaceutical Inc is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening rare diseases. The company’s research and development efforts center on genetic and metabolic disorders, where patient populations are often small and treatment options are limited.

BioMarin’s marketed products include Voxzogo (vosoritide) for children with achondroplasia and open growth plates, Palynziq (pegvaliase) and Kuvan (sapropterin dihydrochloride) for phenylketonuria, Brineura (cerliponase alfa) for late-infantile neuronal ceroid lipofuscinosis type 2, Vimizim (elosulfase alfa) for Morquio A syndrome, and Naglazyme (galsulfase) for mucopolysaccharidosis VI.